Navigation Links
FDA Approves First Combo Drug for Diabetes, Cholesterol

FRIDAY, Oct. 7 (HealthDay News) -- A first-of-a-kind pill that treats both type 2 diabetes and high cholesterol was approved by the U.S. Food and Drug Administration on Friday.

Juvisync is a prescription medication that contains two previously approved medicines, sitagliptin (Januvia) and simvastatin (Zocor). Sitagliptin helps lower blood sugar levels, and simvastatin reduces the amount of "bad" low-density lipoprotein in the blood.

Many of the estimated 20 million people in the United States with type 2 diabetes also have high cholesterol, the FDA researchers noted. The two conditions are associated with increased risk of chronic conditions, such as heart disease, stroke, kidney disease and blindness.

"This is the first product to combine a type 2 diabetes drug with a cholesterol-lowering drug in one tablet," Dr. Mary H. Parks, director of the division of metabolism and endocrinology products in the FDA's Center for Drug Evaluation and Research, said in the news release.

One expert said the two-in-one pill might be of help to some patients.

"Certainly, as 20 million people are suffering with diabetes in this country, aggressive proactive prevention is critical," noted Dr. Suzanne Steinbaum, a preventive cardiologist at Lenox Hill Hospital in New York City. "Perhaps this is the first medication which can help successfully address these significant and pervasive risk factors."

The Juvisync dosage strengths approved by the FDA are 100 milligrams (mg) of sitagliptin with 10 mg, 20 mg or 40 mg of simvastatin. The drug maker -- MSD International GmbH Clonmel, Co. of Ireland -- has promised to develop Juvisync doses with 50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg of sitagliptin/simvastatin, according to an FDA news release.

Patients who require a 50-mg dose of sitagliptin should continue to use single-ingredient sitagliptin tablets with that dose until Juvisync with 50 mg of sitagliptin is available, the FDA said.

"To ensure safe and effective use of this product, tablets containing different doses of sitagliptin and simvastatin in fixed-dose combination have been developed to meet the different needs of individual patients. Dose selection should factor in what other drugs the patient is taking," Parks added.

The most common side effects of Juvisync include: upper respiratory infection; stuffy or runny nose and sore throat; headache, muscle and stomach pain; constipation; and nausea.

More information

The U.S. Agency for Healthcare Research and Quality has more about medicines for type 2 diabetes.

-- Robert Preidt

SOURCE: Suzanne Steinbaum, MD, preventive cardiologist, Lenox Hill Hospital, New York City; U.S. Food and Drug Administration, news release, Oct. 7, 2011

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kaiser Permanente Approves $170 Million in Community Benefit Grants in 2009
2. The American Association of Anatomists approves guidelines for body donation programs
3. Golden Meditech Shareholders Approves of Name Change
4. New Jersey Approves Initiative to Expand the Number of Wound Care Certified Professionals
5. Congress Approves Bill Curbing Internet Tobacco Sales in Victory for Kids and Taxpayers
6. House of Representatives Approves Health-Care Reform Bill
7. New York State Office of Mental Health Approves New High Performance Polycarbonate Sheet for Use in All Facilities
8. FDA Approves Stemedica IND for Ischemic Stroke Clinical Trial
9. FDA approves first human neural stem cell clinical trial to treat brain tumors
10. Early detection of cancer: The FDA approves procedure discovered by EPFL researchers
11. FDA approves Merz Pharmaceuticals Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm
Post Your Comments:
Related Image:
FDA Approves First Combo Drug for Diabetes, Cholesterol
(Date:11/25/2015)... Missouri (PRWEB) , ... November 25, 2015 , ... ... HEAL, will provide scholarships for people struggling with eating disorders as a result ... from the second annual event, held at Fox Run Golf Club in Eureka, ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination of recycled ... way for homeless people to have a more dignified and comfortable night’s sleep. ... they are repurposing plastic bags into sleeping mats for the homeless. The ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something ... winners of the Create Real Impact awards. California Casualty is proud to ... the tide of distracted and reckless driving, the number one killer of young drivers. ...
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA , ... now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. This ... cutting tools, such as the scalpel and high-speed drill, which can both cause patients ...
(Date:11/24/2015)... ... November 24, 2015 , ... ThirdLove, the ... sale a week early, offering 40% off select bras and underwear styles, now ... through both mobile fit technology and the latest fashion, quickly becoming the next ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)...  Array BioPharma Inc. (Nasdaq: ARRY ) ... Ron Squarer , will present at the Piper ... public is welcome to participate in the conference ... Jaffray Annual Healthcare ConferencePresenter:  , Ron Squarer, Chief ... Eastern Time Webcast: , ...
(Date:11/24/2015)... NEWPORT NEWS, Va. , Nov. 24, 2015 /PRNewswire/ ... that they have signed an agreement for DILON to ... select geographies across the globe. The signing of this distribution ... GE,s Discovery NM750b Molecular Breast Imaging system and is ... ways to provide better healthcare solutions for clinicians and ...
(Date:11/24/2015)... 2015 . ... adds Latest Guidebook for Chinese Medical Device GMP ... in November 2015 to the medical devices market ... at . China ... global economies with a fifth population in the ...
Breaking Medicine Technology: